Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 6,140,000 shares, an increase of 20.2% from the November 30th total of 5,110,000 shares. Approximately 10.5% of the shares of the stock are short sold. Based on an average trading volume of 1,970,000 shares, the days-to-cover ratio is presently 3.1 days.
Tempus AI Stock Down 0.5 %
Shares of TEM stock traded down $0.17 on Friday, hitting $35.12. The company’s stock had a trading volume of 4,444,572 shares, compared to its average volume of 1,624,103. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The firm’s fifty day moving average price is $50.06.
Insider Transactions at Tempus AI
In other Tempus AI news, Director David R. Epstein sold 620 shares of Tempus AI stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $41.81, for a total transaction of $25,922.20. Following the transaction, the director now directly owns 27,894 shares in the company, valued at approximately $1,166,248.14. The trade was a 2.17 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 845,041 shares of company stock valued at $35,125,473 in the last three months.
Institutional Trading of Tempus AI
Wall Street Analyst Weigh In
Several research firms recently weighed in on TEM. Piper Sandler reissued a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Bank of America upped their target price on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Guggenheim started coverage on shares of Tempus AI in a report on Monday, December 9th. They set a “buy” rating and a $74.00 price target for the company. Loop Capital boosted their price objective on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, October 15th. Finally, Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $56.00.
About Tempus AI
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Read More
- Five stocks we like better than Tempus AI
- Most active stocks: Dollar volume vs share volume
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- What is the Nikkei 225 index?
- These 3 Quirky ETFs May Be Strong Plays in 2025
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.